{'fraction_non_alphanumeric': 0.025167785234899327, 'fraction_numerical': 0.026845637583892617, 'mean_word_length': 5.633333333333334, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Targeting the Th17 pathway in psoriasis

In recent years, the classic paradigm of Th1/Th2 CD4+ T cell‐mediated immunity has evolved to include the IL‐17A‐producing Th17 subset, a distinct proinflammatory CD4+ T cell lineage. Accumulating evidence suggests that IL‐17A and the Th17 pathway may play an important role in the pathology of psoriasis and in other immune‐mediated inflammatory diseases. This review summarizes the preclinical and clinical evidence implicating Th17 cells in psoriasis and the therapeutic approaches, approved or under investigation, to target this pathway in psoriasis.